HAYWARD, Calif. / Nov 19, 2024 / Business Wire / Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December:
Evercore 7th Annual HealthCONx Conference
Date: Tuesday, December 3rd, 2024
Location: Coral Gables, FL
Format: Fireside chat & 1x1 meetings
Time: 7:55 a.m. ET
Citi 2024 Global Healthcare Conference
Date: Wednesday, December 4th, 2024
Location: Miami, FL
Format: 1x1 meetings only
Live webcasts of the fireside chats and panel will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
| Last Trade: | US$8.28 |
| Daily Change: | -0.25 -2.93 |
| Daily Volume: | 1,171,905 |
| Market Cap: | US$757.700M |
May 06, 2025 February 25, 2025 February 18, 2025 February 18, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
